Big Board

Content Ideas
Result Content Idea Research
Result Content Idea Research
1 Tecentriq-Avastin Combo Approved in Europe for Advanced or...
2 Avastin and Tecentriq combination wins approval in China and Europe
3 Systemic Therapy Advances Provide More Treatment Options in HCC
4 Key Capital to Fast-track Breakthrough Liver Cancer Immunotherapy
5 Nexavar: Side effects, uses, dosage, and more
6 Europe approves Roche's Tecentriq liver cancer combination
7 Roche, Blueprint catches up with Lilly as Gavreto snags FDA thyroid cancer nod
8 Nexavar (sorafenib)
9 Bolar exemption does not apply to offering to sell patented drugs
10 Innovent Biologics Biosimilar Combination Surpasses Sorafenib in ORIENT-32
11 Long HCC pipeline marks change for a previously stagnant market
12 Sintilimab/Bevacizumab Biosimilar Combo Shows Superior OS, PFS Over Sorafenib in Advanced Unresectable HCC
13 Liver cancer outcomes improving as physicians gain experience with Nexavar
14 TACE plus Nexavar for unresectable HCC improves progression-free survival
15 Long HCC pipeline marks change for previously stagnant market, says an
16 Atezolizumab/Bevacizumab Lays the Groundwork for Optimal Sequencing in HCC
17 Unlocking the Potential of Targeted Treatment Options for HCC
18 Bayer's dominance in liver cancer challenged
19 Exploring Therapies in Combination With Cytoreductive Nephrectomy in RCC
20 Multiple Studies Provide Efficacy Results for Lenvatinib in Thyroid Cancer
21 MiNA raises $30M to take small activating RNA into phase 2
22 Roche's Tecentriq gets a green light to challenge Bayer with first-in-class liver cancer nod
23 Nexavar receives final appraisal for primary liver cancer
24 Discontinuing Nexavar leads to increased survival in HCC
25 Bayer dials up Roundup settlement price—and takes a $11B write-down—as pharma fails to pick up slack
26 Roche nabs frontline OK for Avastin/Tecentriq in common liver cancer, besting an old Bayer drug
27 Tecentriq, Avastin combo trumps Nexavar in liver cancer
28 Nexavar beneficial in liver cancer regardless of prognostic factors
29 Bristol-Myers Squibb's Opdivo Fails to Show Superiority to Bayer's Nexavar in Liver Cancer
30 Tecentriq Plus Avastin Now Approved for Liver Cancer
31 Renal Cell Cacinoma Drugs Market Size 2020 Demand, Global Trend, News, Business Growth, Top Key Players Update, Business Statistics and Research Methodology by Forecast to 2026
32 Bayer's Nexavar receives Japanese approval
33 Lenvima non-inferior to Nexavar in treating unresectable HCC
34 Tarus Therapeutics Expands R&D Team with Appointment of Brian Schwartz, MD as Interim Chief Medical Officer and Head of the Scientific Advisory Board
35 Stivarga and Opdivo Provide Comparable Survival Benefits for People With Liver Cancer
36 FDA Approves Immunotherapy Combo for Liver Cancer
37 Kaelin Speaks to the Future of I/O, HIF-2α, CDK4/6 Inhibitors in VHL Disease–Associated RCC
38 Enlivex Appoints Former ArQule, Inc. Executive Dr. Brian Schwartz to the Company's Board of Directors
39 Phase 3 ORIENT-32 Trial Shows Promise for First-Line Treatment Combo in HCC
40 US FDA Approves NEXAVAR® (sorafenib) for the Treatment of Patients with Locally Recurrent or Metastatic, Progressive, Differentiated Thyroid Carcinoma Refractory to Radioactive Iodine Treatment
41 NICE rejects Bayer's Nexavar for liver cancer
42 Atezolizumab/Bevacizumab Approved in Europe for Advanced or Unresectable HCC
43 Keytruda Approved for Liver Cancer Patients Who Had Used Nexavar
44 Renal Cell Cacinoma Drugs Market Booming Demand Leading To Exponential CAGR Growth By 2026 | DataIntelo
45 New Drug Combo Potentially Practice Changing in Advanced HCC
46 Bayer to Showcase New Data from Evolving Oncology Portfolio at ESMO Virtual Congress 2020
47 Tecentriq-Avastin Combo for Liver Cancer Recommended for EU Approval
48 FDA to Review Tecentriq-Avastin Combo for Newly Diagnosed Advanced...
49 Roche takes aim at Bayer's liver cancer share with big Tecentriq-Avastin win
50 Amgen Inc. (AMGN) Rises 2.04% for November 27
51 As Roundup suits pile on, Bayer's drugs deliver a surprisingly good show
52 Real-World Data Support Use of Multikinase Inhibitors in Differentiated Thyroid Cancer
53 FDA Approves Tecentriq-Avastin Combo for Newly Diagnosed Advanced...
54 Sorafenib 'New Standard of Care' for Patients With Desmoid Tumors
55 FDA Grants Accelerated Approval to Opdivo-Yervoy Combo for Advanced HCC
56 Indian High Court rules against Bayer on Nexavar and Xarelto API expor
57 Pexa-Vec/Nexavar Combination Fails Phase III Trial in Liver Cancer
58 FDA Approves New Liver Cancer Combo for Previously Treated Patients
59 Merck, Eisai's Keytruda-Lenvima combo stonewalled in liver cancer after Roche's first-in-class green light
60 Expert Recognizes Expansion of HCC Treatment Options During Liver Cancer Awareness Month
61 Bayer cancer drug faces new Nexavar patent problems in India
62 Nexavar fails late-stage breast cancer trial
63 Roche's Tecentriq/Avastin combination approved by European Commission
64 Global Renal Cell Cacinoma Drugs Market 2020 Key Stakeholders, Growth Opportunities, Value Chain and Sales Channels Analysis 2025
65 FDA Approves Opdivo-Yervoy Combo for Previously Treated Liver Cancer
66 Kidney Cancer Drugs Market Report 2020 Potential Effect on Upcoming Future Growth by Top Vendors: Pfizer, Abbott Laboratories, Glaxosmithkline PLC, Novartis AG
67 Lenvima to get benefit as 1st-line treatment of hepatocellular carcinoma
68 Real-Life Analysis of Nivolumab in Patients With HCC Align With Clinical Trial Data
69 Comparing Sorafenib and Lenvatinib for the Frontline Treatment of Advanced HCC
70 UPDATED: Bayer counts on Nexavar-Stivarga 'continuum' to protect its liver-cancer lead
71 Cabometyx: Side effects, dosage, uses, and more
72 Cabometyx, Opdivo, Yervoy Combo Shows Benefits in Advanced HCC, Trial Data Show
73 NICE bars NHS access to Lenvima, Nexavar for thyroid cancer
74 Edited Transcript of NATP.NS earnings conference call or presentation 13-Nov-20 5:30am GMT
75 Nexavar shown to significantly extend survival for patients with advanced liver cancer
76 Renal Cell Cacinoma Drugs Market
77 'Momentous' Data for First-Line Combo in Liver Cancer
78 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market 2020-2026: Key Vendor Landscape By Regional Output, Demand By Countries And Future Growth
79 ASCO: Merck, Eisai pad case for liver cancer nod with Keytruda-Lenvima combo data
80 Asco 2020 – after Tecentriq’s liver win the spotlight falls on Merck and Astra
81 Bayer keeps cheap Nexavar copy from being exported from India
82 Kidney Cancer Drugs Market Report 2020 Expected to Generate New Growth Opportunities by 2026| Pfizer, Abbott Laboratories, Glaxosmithkline PLC, Novartis AG, Bayer AG, Active Biotech
83 How To Charge $1.6 Million For a New Drug And Get Away With It
84 Who can make Gilead’s coronavirus drug, licence free?
85 Renal Cell Cacinoma Drugs Market Analysis, Trends, Top Manufacturers, Share, Growth, Statistics, Opportunities & Forecast To 2026
86 Bayer 2020: End in sight – PharmaLive
87 Nexavar significantly extends overall survival by 44 percent in liver cancer patients
88 Chemotherapy vs Immunotherapy: China's Liver Cancer Market Outlook
89 Experimental Targeted Therapy Pill Extends Lives of Patients with Metastatic Renal Cell Carcinoma
90 A Major Turnaround for Liver Cancer
91 Global Kidney Cancer Drugs Market Report 2020: Focus on Nexavar, Sutent, Afinitor, Votrient, Avastin, Inlyta, Torisel, Proleukin
92 What You Need to Know About the FDA's Approval of Opdivo-Yervoy for Hepatocellular Carcinoma
93 Good, But Not Good Enough: FDA Rejects Merck-Eisai Combo for Liver Cancer
94 Bayer fails to suspend sales of generic Nexavar in India
95 Dr. Kim on the Safety Profile of Atezolizumab/Bevacizumab in HCC
96 Roche's Tecentriq/Avastin combo improves survival in liver cancer
97 Drug Duo Is Promising in Older Patients With Advanced HCC
98 Natco shares gain on its partner Mylan’s tentative nod for generic Nexavar in US
99 Coronavirus compounds trouble for Bayer
100 AZ nabs a positive study for Imfinzi plus tremelimumab in liver cancer